Illumina has announced that the company has filed a new patent infringement suit against Ariosa Diagnostics, Inc. and its parent company, Roche Molecular Systems, Inc. Illumina is seeking all available remedies.
The new suit, filed in the U.S. District Court for the Northern District of California, is based on Ariosa’s infringement of U.S. Patent No. 7,955,794 (the ‘794 patent), entitled “Multiplex Nucleic Acid Reactions.” The suit is focused on Ariosa’s Microarray-based version of its Harmony™ Prenatal Test.
Illumina and its wholly owned subsidiary, Verinata Health, Inc., previously filed suits in the U.S. District Court for the Northern District of California against Ariosa accusing its Sequencing-based version of the Harmony Prenatal Test of infringing the ‘794 patent and U.S. Patent No. 8,296,076 and U.S. Patent No. 8,318,430. Those previous suits remain pending.